The possibly fatal reason gummies sold at Aldi, BJ's and on Amazon got recalled
Conflicting test results indicating a potential allergy danger caused the manufacturer of vitamin B12 gummies to recall them nationwide.
Vita Warehouse made Welby Vitamin B12 Energy Support gummies 1000 mcg for Aldi, Berkely Jensen Vitamin B12 1000 mcg gummies for BJ's Warehouse Club, and sells VitaGlobe Vitamin B12 Extra Strength gummies through its website. The gummies should be peanut free, as indicated on the label's ingredient listing.
But, Vita Warehouse said in its FDA-posted recall notice, Aldi's routine testing for allergen listing accuracy 'indicated a potential presence of a peanut allergen. Although internal testing conducted by Vita Warehouse Corp. has verified the absence of peanuts in the product, the recall is being initiated out of an abundance of caution to ensure consumer safety and trust.'
Because, if Aldi's testing is correct and someone with a peanut allergy gulps the gummies, Vita Warehouse's notice says, there's a 'risk of serious or life-threatening allergic reaction.'
Each of the bottles has lot No. 248046601 with an October 2026 expiration date of October 2026. If you have them and they might be taken by someone who has a peanut allergy, return them to your seller for a refund.
If you have questions, call Vita Warehouse at 855-214-0100, Monday through Friday, 7:30 a.m. to 4 p.m., Eastern time.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
3 hours ago
- Business Insider
Incyte announces FDA extends review period for Opzelura sNDA
The company states: 'Incyte (INCY) announced that the FDA has extended the review period for the supplemental New Drug Application, sNDA, for ruxolitinib cream, Opzelura, a topical Janus kinase inhibitor, for the treatment of children 2-11 years old with mild to moderate atopic dermatitis. The PDUFA action date has been extended by three months to September 19, 2025. The FDA extended the PDUFA action date to allow time to review additional chemistry, manufacturing and controls data on the 0.75% strength submitted by Incyte in response to a recent FDA information request.' Steven Stein, M.D., Chief Medical Officer, Incyte stated: 'We are confident in the potential of ruxolitinib cream to become an important non-steroidal, topical treatment option for pediatric patients with atopic dermatitis and we will continue to work closely with the FDA to ensure the Agency has all of the information needed to complete its review.' Confident Investing Starts Here:
Associated Press
6 hours ago
- Associated Press
IBN Coverage: HeartBeam (NASDAQ: BEAT) Earns FDA Clearance for First Cable-Free ECG System for Arrhythmia Detection
This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - June 20, 2025 ( NEWMEDIAWIRE ) - HeartBeam (NASDAQ: BEAT) announced it has received FDA 510(k) clearance for its flagship ECG system, a first-of-its-kind, credit card-sized, cable-free device designed to deliver high-fidelity, three-directional cardiac recordings for arrhythmia evaluation. The clearance marks a major regulatory milestone and accelerates HeartBeam's plans to improve access to timely, remote cardiac care. When symptoms arise, patients use the app-guided system to record a 30-second ECG, which is automatically uploaded to the cloud for physician review in the context of medical history. The company will soon launch an Early Access Program to engage early adopters and providers ahead of broader commercialization. This foundational clearance also sets the stage for future advancements, including 12-lead ECG synthesis, AI-based arrhythmia detection, and remote heart attack risk scoring. HeartBeam's long-term vision is to revolutionize cardiac care by enabling continuous, predictive insights outside traditional clinical settings. To view the full press release, visit About HeartBeam Inc. HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart's electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care - all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement. For more information, visit NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: The latest news and updates relating to BEAT are available in the company's newsroom at Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading 'Risk Factors' discussed under the caption 'Item 1A. Risk Factors' in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption 'Item 1A. Risk Factors' in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law. About IBN IBN is a cutting-edge communications and digital engagement platform providing tailored Platform Solutions for select private and public companies. Over the course of 19+ years, IBN has introduced over 70 investor facing brands to the investment public and amassed a collective audience of millions of social media followers. These distinctive investor brands amplify recognition and reach as well as help fulfill the unique needs of our rapidly growing and diverse base of client-partners. IBN will continue to expand our branded network of influential properties as well as leverage the energy and experience of our team of professionals to best serve our clients. IBN's Platform Solutions provide access to: (1) our Dynamic Brand Portfolio (DBP) through 70+ investor facing brands; (2) article and editorial syndication to 5,000+ news outlets; (3) full-scale distribution to a growing Social Media Network (SMN) ; (4) a network of wire solutions via InvestorWire to effectively reach target markets and demographics; (5) Press Release Enhancement to ensure accuracy and impact; (6) a full array of corporate communications solutions; and (7) total news coverage solutions. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: Media Contact IBN Los Angeles, California 310.299.1717 Office [email protected]
Yahoo
8 hours ago
- Yahoo
Little Remedies honey cough syrup recalled nationwide: What parents need to know
As parents, we do everything we can to keep our children safe—especially when they're sick. That's why a new nationwide recall of a popular over-the-counter children's cough medicine is raising serious concern. Medtech Products Inc. has voluntarily recalled several lots of Little Remedies® Honey Cough Syrup after the U.S. Food and Drug Administration (FDA) found the presence of Bacillus cereus, a harmful bacteria that can cause foodborne illness—and in severe cases, even death. The recalled syrup, a go-to for many parents looking for natural relief for their child's cough, was sold online and in stores across the U.S. between December 2022 and June 2025. While no serious injuries have been reported as of now, the company is urging families to stop using the affected products immediately. Here's what you need to know to keep your little ones safe. The recall affects Little Remedies® Honey Cough Syrup, sold in 4 FL OZ (118 mL) amber bottles, commonly found in pharmacies, grocery stores, and online retailers. The syrup is marketed as a gentle, natural remedy made with honey to soothe coughs in children — but the recent discovery of Bacillus cereus contamination has made certain lots unsafe for use. According to the official FDA notice, the bacteria was detected in certain lots, prompting a recall due to concerns about shelf stability and potential health risks. While no other Little Remedies® products are affected, all lots of this particular syrup still within the expiration date have been included in the recall out of an abundance of caution. Here are the affected lot numbers and expiration dates: Lot 0039 – Expires 11/2025 Lot 0545 – Expires 01/2026 Lot 0640 – Expires 02/2026 Lot 0450 – Expires 05/2026 Lot 1198 – Expires 12/2026 Each recalled bottle has a UPC of 7-56184-10737-9 and should have the lot number printed on both the label and the bottom of the box. If you have one of these in your medicine cabinet, read on for what steps to take next. Bacillus cereus is a type of bacteria that can cause foodborne illness when ingested — especially when it grows in products that are no longer shelf-stable. While it may sound unfamiliar to many parents, the symptoms it causes are unfortunately very recognizable. There are two common types of illness linked to B. cereus: The first appears 1 to 6 hours after exposure and typically causes nausea, vomiting, and stomach cramps. The second appears 8 to 16 hours after exposure, with symptoms including diarrhea and abdominal pain. In some cases, the diarrhea may be severe and watery. In most healthy children, these symptoms may pass on their own. However, exposure to high levels of can lead to more serious illness — and in rare cases, it can be fatal. If your child has consumed the recalled syrup and shows any of these symptoms, it's important to contact your pediatrician or seek medical attention right away. When in doubt, trust your instincts — you know your child best. Related: Here's how I'm preparing for my kids' sick days this year If you have a bottle of Little Remedies® Honey Cough Syrup at home, the first step is to stop using it immediately — even if your child has taken it without any symptoms. Check both the UPC (7-56184-10737-9) and the lot number, which can be found on the bottle label and the bottom of the box. Here's what to do next: If your child has taken the syrup and is experiencing nausea, vomiting, diarrhea, or stomach pain, call your pediatrician right away. If your child seems fine, monitor them closely for symptoms for up to 24 hours. To request a refund or report an issue, you can contact Medtech directly: Call: (800) 754-8853 (Monday–Friday, 8:30 a.m. to 5:30 p.m. ET) Email: medicalaffairs@ Website: If you or your healthcare provider believe your child experienced a reaction to the product, you can also report it through the FDA's MedWatch program at It's always okay to ask questions, trust your instincts, and reach out for guidance when your child's health is involved. Related: Target recalls baby food over lead concerns—here's what parents should do Recalls like this can feel unsettling, especially when they involve products we trust. But by staying informed and taking quick action, you're doing exactly what your child needs. No serious injuries have been reported, and the recall is precautionary — but it's always better to be safe. If you have concerns, talk to your pediatrician. When it comes to your child's health, caution is care.
